Wellington Management Group LLP Lowers Position in Becton, Dickinson and Company $BDX

Wellington Management Group LLP lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 89.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 111,058 shares of the medical instruments supplier’s stock after selling 959,347 shares during the period. Wellington Management Group LLP’s holdings in Becton, Dickinson and Company were worth $25,439,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of BDX. GQG Partners LLC purchased a new stake in Becton, Dickinson and Company in the 1st quarter worth approximately $689,833,000. Vanguard Group Inc. lifted its position in shares of Becton, Dickinson and Company by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after buying an additional 1,259,750 shares in the last quarter. Nuveen LLC purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at approximately $211,097,000. GAMMA Investing LLC lifted its position in shares of Becton, Dickinson and Company by 29,654.0% during the 1st quarter. GAMMA Investing LLC now owns 744,445 shares of the medical instruments supplier’s stock valued at $170,523,000 after buying an additional 741,943 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Becton, Dickinson and Company by 10.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after buying an additional 667,957 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 2.5%

Shares of BDX opened at $194.6980 on Tuesday. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The company has a market capitalization of $55.81 billion, a PE ratio of 35.02, a price-to-earnings-growth ratio of 1.49 and a beta of 0.20. The stock has a fifty day simple moving average of $181.10 and a two-hundred day simple moving average of $194.78. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same period last year, the company earned $3.50 EPS. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on BDX shares. Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. William Blair lowered Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 1st. Stifel Nicolaus decreased their target price on Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. Morgan Stanley increased their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Finally, Bank of America lowered Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 target price on the stock. in a research report on Thursday, May 1st. Four investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $211.44.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Claire Fraser sold 863 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the sale, the director directly owned 23,143 shares of the company’s stock, valued at $4,450,398.90. This trade represents a 3.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Shan sold 1,166 shares of the firm’s stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the sale, the executive vice president directly owned 4,575 shares of the company’s stock, valued at $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,214 shares of company stock valued at $579,206 in the last three months. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.